Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...

Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next ...

Lilly to buy biopharma company Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera: Indianapolis Tuesday, April 28, 2026, 14:00 Hrs [IST] E ...

Lilly will pay up to $2.3B for Ajax and its AJ1‑11095 myelofibrosis drug; proof‑of‑concept data expected in 2026.

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...

Eli Lilly will acquire Ajax Therapeutics for up to $2.3 billion, securing rights to its experimental myelofibrosis treatment AJ1-11095. The once-daily oral JAK2 inhibitor is in early-stage trials for ...

Eli Lilly and Company (NYSE:LLY) dropped 0.45% intraday after announcing a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, inclusive of an upfront payment and subsequent ...

Some blood cancers move with eerie patience. A patient can feel well for years, their blood counts looking steady, their ...